CVS Health Valuation
Is CVSCL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of CVSCL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: CVSCL (CLP57949) wird unter unserer Schätzung des Fair Value (CLP182873.78) gehandelt.
Deutlich unter dem Marktwert: CVSCL wird um mehr als 20 % unter dem Marktwert gehandelt.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CVSCL?
Other financial metrics that can be useful for relative valuation.
| What is CVSCL's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$93.00b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.5x |
| Enterprise Value/EBITDA | 8.7x |
| PEG Ratio | 1.6x |
Price to Earnings Ratio vs Peers
How does CVSCL's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 31x | ||
CI Cigna Group | 19.8x | 10.3% | US$102.4b |
LH Laboratory Corporation of America Holdings | 46.8x | 24.1% | US$17.8b |
FRE Fresenius SE KGaA | 40.2x | 22.8% | €14.2b |
DGX Quest Diagnostics | 17.1x | 7.5% | US$14.7b |
CVSCL CVS Health | 11.1x | 7.2% | CL$93.0b |
Price-To-Earnings gegen Gleichaltrige: CVSCL ist ein guter Wert, wenn man sein Price-To-Earnings Verhältnis (11.5x) mit dem Durchschnitt der anderen Unternehmen (26.8x) vergleicht.
Price to Earnings Ratio vs Industry
How does CVSCL's PE Ratio compare vs other companies in the Global Healthcare Industry?
Price-To-Earnings gegen Industrie: CVSCL ist aufgrund seines Price-To-Earnings Verhältnisses (11.5x) im Vergleich zum Global Healthcare Branchendurchschnitt (23x) ein guter Wert.
Price to Earnings Ratio vs Fair Ratio
What is CVSCL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 11.1x |
| Fair PE Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Earnings Fair Ratio von CVSCL für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CL$57,949.00 | CL$85,199.59 +47.0% | 7.5% | CL$98,350.58 | CL$73,524.22 | n/a | 26 |
| Mar ’25 | CL$57,949.00 | CL$86,762.70 +49.7% | 7.0% | CL$99,578.34 | CL$74,442.06 | n/a | 25 |
| Feb ’25 | CL$57,949.00 | CL$82,540.05 +42.4% | 7.4% | CL$94,682.64 | CL$72,832.80 | n/a | 24 |
| Jan ’25 | CL$57,949.00 | CL$78,797.64 +36.0% | 8.6% | CL$92,690.00 | CL$67,735.00 | n/a | 24 |
| Dec ’24 | CL$57,949.00 | CL$76,689.79 +32.3% | 9.2% | CL$90,727.52 | CL$66,300.88 | n/a | 23 |
| Nov ’24 | CL$57,949.00 | CL$80,865.38 +39.5% | 10.4% | CL$98,628.20 | CL$68,143.12 | n/a | 23 |
| Oct ’24 | CL$57,949.00 | CL$82,712.10 +42.7% | 10.3% | CL$99,464.75 | CL$68,721.10 | n/a | 24 |
| Sep ’24 | CL$57,949.00 | CL$78,824.92 +36.0% | 9.8% | CL$93,934.50 | CL$64,900.20 | n/a | 24 |
| Aug ’24 | CL$62,536.00 | CL$79,268.58 +26.8% | 12.2% | CL$100,872.00 | CL$60,523.20 | n/a | 23 |
| Jul ’24 | CL$58,409.00 | CL$79,809.00 +36.6% | 16.6% | CL$114,897.64 | CL$61,064.48 | n/a | 24 |
| Jun ’24 | CL$54,490.00 | CL$80,656.47 +48.0% | 16.6% | CL$115,093.55 | CL$61,168.60 | n/a | 23 |
| May ’24 | CL$86,571.00 | CL$88,055.14 +1.7% | 13.3% | CL$115,329.50 | CL$69,359.00 | n/a | 22 |
| Apr ’24 | CL$86,571.00 | CL$89,425.26 +3.3% | 10.0% | CL$112,928.53 | CL$75,022.45 | CL$57,949.00 | 21 |
| Mar ’24 | CL$86,571.00 | CL$91,356.71 +5.5% | 9.4% | CL$114,548.72 | CL$76,098.80 | CL$57,949.00 | 21 |
| Feb ’24 | CL$86,571.00 | CL$96,304.10 +11.2% | 6.5% | CL$107,120.00 | CL$82,400.00 | CL$57,949.00 | 23 |
| Jan ’24 | CL$86,571.00 | CL$102,293.84 +18.2% | 4.9% | CL$112,320.00 | CL$91,584.00 | CL$57,949.00 | 23 |
| Dec ’23 | CL$86,571.00 | CL$108,778.83 +25.7% | 4.9% | CL$119,221.70 | CL$97,211.54 | CL$57,949.00 | 23 |
| Nov ’23 | CL$86,571.00 | CL$116,465.28 +34.5% | 5.8% | CL$126,795.50 | CL$97,535.00 | CL$57,949.00 | 23 |
| Oct ’23 | CL$86,571.00 | CL$108,747.91 +25.6% | 4.4% | CL$116,069.20 | CL$99,105.24 | CL$57,949.00 | 23 |
| Sep ’23 | CL$86,571.00 | CL$107,594.53 +24.3% | 4.4% | CL$115,043.50 | CL$98,229.45 | CL$57,949.00 | 23 |
| Aug ’23 | CL$86,571.00 | CL$116,457.08 +34.5% | 5.0% | CL$126,015.75 | CL$101,209.50 | CL$62,536.00 | 24 |
| Jul ’23 | n/a | CL$101,890.50 0% | 5.1% | CL$110,058.20 | CL$88,393.20 | CL$58,409.00 | 24 |
| Jun ’23 | n/a | CL$96,933.82 0% | 5.2% | CL$104,527.35 | CL$83,951.10 | CL$54,490.00 | 23 |
| May ’23 | n/a | CL$95,111.91 0% | 4.3% | CL$100,676.25 | CL$86,984.28 | CL$86,571.00 | 23 |
| Apr ’23 | n/a | CL$95,138.60 0% | 4.3% | CL$100,601.25 | CL$86,919.48 | CL$86,571.00 | 24 |
Analysten-Prognose: Das Kursziel liegt mehr als 20% über dem aktuellen Aktienkurs, und die Analysten liegen in einem statistisch sicheren Bereich der Übereinstimmung.